

Technology Appraisal Committee Meeting (Committee B)

Minutes: Confirmed

Date and Time: Wednesday 6 April 2016 from 10am to 6pm

Venue: 10 Spring Gardens
London
SW1A 2BU

Present:	1. Dr Amanda Adler (Chair)	Present for all notes
	2. Dr Ray Armstrong	Present for all notes
	3. Dr Jeff Aronson	Present for all notes
	4. Professor John Cairns	Present for all notes
	5. Dr Mark Glover	Present for all notes
	6. Dr Neil Iosson	Present for all notes
	7. Mrs Anne Joshua	Present for all notes
	8. Dr Rebecca Kearney	Present for all notes
	9. Dr Sanjay Kinra	Present for all notes
	10. Dr Miriam McCarthy	Present for all notes
	11. Professor Ruairidh Milne	Present for all notes
	12. Professor Stephen Palmer	Present for all notes
	13. Dr Sanjeev Patel (Vice-Chair)	Present for all notes
	14. Professor John Pounsford	Present for all notes
	15. Dr Danielle Preedy	Present for all notes
	16. Dr Nigel De-Kare Silver	Present for all notes
	17. Dr Marta Soares	Present for all notes
	18. Dr Nicky Welton	Present for all notes

In attendance:

Meindert Boysen	Programme Director, National Institute for Health and Care Excellence	Present for all notes
Dr Melinda Goodall	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Jeremy Powell	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Dr Rosie Lovett	Technical Adviser, National Institute for Health and Clinical Excellence	Present for notes 1 to 18

Raisa Sidhu	Technical Adviser, National Institute for Health and Clinical Excellence	Present for notes 19 to 31
Chris Griffiths	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 32 to 44
Professor Chris Hyde	Professor of Public Health, PenTAG	Present for notes 1 to 16
Nicola Huxley	Associate Research Fellow, PenTAG	Present for notes 1 to 16
Dr Linda Long	Research Fellow, PenTAG	Present for notes 1 to 16
Ken Campbell	Scientific and Medical Education Specialist, Myeloma UK, nominated by Myeloma UK	Present for notes 5 to 15
Professor Steve Schey	Consultant Haematologist, Kings College Hospital Foundation Trust, nominated by Celgene	Present for notes 5 to 15
Professor Kwee Yong	Consultant Haemato- oncologist / Chair of UK Myeloma Forum/University College London nominated by UK Myeloma Forum / Royal College of Pathologists / BSH	Present for notes 5 to 15
Professor Craig Ramsay	HCA Programme Director and Senior Statistician, Aberdeen HTA Group	Present for notes 19 to 29
Dr Miriam Brazzelli	Senior Research Fellow, Aberdeen HTA Group	Present for notes 19 to 29
Dr Ewen Cummins	Health Economist, Aberdeen HTA Group	Present for notes 19 to 29
Professor Aileen Clarke	Professor of Public Health & Health Services Research, Warwick Evidence	Present for notes 32 to 42
Emma Loveman	Senior Research Fellow, Warwick Evidence	Present for notes 32 to 42

Non-public observers:

Helen Barnett	Medical Editor, NICE	Present for all notes
---------------	----------------------	-----------------------

Chloe Kastoryano	Public Involvement Adviser, Patient Involvement Programme, NICE	Present for notes 1 to 18
Pilar Pinilla-Dominguez	Technical Advisor, Scientific Advice, NICE	Present for notes 19 to 31
Irina Voicechovskaja	Technical Analyst, Technology Appraisals, NICE	Present for all notes

Notes

Welcome

1. The Chair welcomed all members of the committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy with bortezomib (partial review of TA171) [ID667], ibrutinib for treating chronic lymphocytic leukaemia [ID749] and ceritinib for previously treated anaplastic lymphoma kinase-positive non-small-cell lung cancer [ID729]
2. The Chair informed the committee of the non-public observers at this meeting: Helen Barnett, Chloe Kastoryano, Pilar Pinilla-Dominguez and Irina Voicechovskaja.
3. Apologies were received from Professor Ken Stein, Mr Mark Chapman, Mr Christopher O'Regan, Mr Alun Roebuck and Mr Nigel Westwood.

Any other Business

4. The committee were given updates on research recommendations and the Cancer Drugs Fund.

Notes from the last meeting

5. The minutes of the meetings held on 3 February 2016 and 2 March 2016 were approved.

Appraisal of lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy with bortezomib (partial review of TA171) [ID667]

Part 1 – Open session

6. The Chair welcomed the invited experts: Professor Chris Hyde, Nicola Huxley, Dr Linda Long, Ken Campbell, Professor Steve Schey and Professor Kwee Yong to the meeting and they introduced themselves to the committee.
7. The Chair welcomed company representatives from Celgene to the meeting.
8. The Chair asked all committee members to declare any relevant interests

- 8.1. Dr Amanda Adler, Dr Ray Armstrong, Dr Jeff Aronson, Professor John Cairns, Dr Mark Glover, Dr Neil Iosson, Mrs Anne Joshua, Dr Rebecca Kearney, Dr Sanjay Kinra, Dr Miriam McCarthy, Professor Ruairidh Milne, Professor Stephen Palmer, Dr Sanjeev Patel, Professor John Pounsford, Dr Danielle Preedy, Dr Nigel De-Kare Silver, Dr Marta Soares and Dr Nicky Welton all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy with bortezomib.
9. The Chair asked all NICE Staff to declare any relevant interests.
 - 9.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy with bortezomib.
10. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
 - 10.1. Professor Chris Hyde, Nicola Huxley and Dr Linda Long declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy with bortezomib.
 - 10.2. Ken Campbell declared a non-personal non-specific financial interest as Myeloma UK receives funding from pharmaceutical companies.
 - 10.2.1. It was agreed that this declaration would not prevent Mr Campbell from participating in this section of the meeting
 - 10.3. Professor Steve Schey declared a personal specific financial interest as he has received honoraria from Celgene and has attended advisory boards for them.
 - 10.3.1. It was agreed that this declaration would not prevent Professor Schey from participating in this section of the meeting
 - 10.4. Professor Kwee Yong declared a personal specific financial interest as she has led many multiple myeloma trials (including on lenalidomide) and has received research funding from Celgene.
 - 10.4.1. It was agreed that this declaration would not prevent Professor Yong from participating in this section of the meeting
11. The Chair introduced the technical advisor, Rosie Lovett and she gave a presentation on the new submission from Celgene.

12. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
13. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
14. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

15. Discussion on confidential information continued. This information was supplied by the company.
16. The Evidence Review Group representatives left the meeting.
17. The committee continued to discuss the clinical and cost effectiveness of lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy with bortezomib.
 - 17.1. The committee decision was based on consensus.
18. The committee agreed to defer a decision on the content of the guidance section of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) until further evidence had been submitted.

Appraisal of ibrutinib for treating chronic lymphocytic leukaemia [ID749]

Part 1 – Open session

19. The Chair welcomed the invited experts: Professor Craig Ramsay, Dr Miriam Brazzelli and Dr Ewen Cummins to the meeting and they introduced themselves to the committee.
20. The Chair welcomed company representatives from Janssen to the meeting.
21. The Chair asked all committee members to declare any relevant interests
 - 21.1. Dr Amanda Adler, Dr Ray Armstrong, Dr Jeff Aronson, Professor John Cairns, Dr Mark Glover, Dr Neil Iosson, Mrs Anne Joshua, Dr Rebecca Kearney, Dr Sanjay Kinra, Dr Miriam McCarthy, Professor Ruairidh Milne, Professor Stephen Palmer, Dr Sanjeev Patel, Professor John Pounsford, Dr Danielle Preedy, Dr Nigel De-Kare Silver, Dr Marta Soares and Dr Nicky Welton all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of ibrutinib for treating chronic lymphocytic leukaemia.
22. The Chair asked all NICE Staff to declare any relevant interests.

- 22.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of ibrutinib for treating chronic lymphocytic leukaemia.
23. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
 - 23.1. Professor Craig Ramsay, Dr Miriam Brazzelli and Dr Ewen Cummins declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of ibrutinib for treating chronic lymphocytic leukaemia.
24. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
25. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
26. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
27. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

28. Discussion on confidential information continued. This information was supplied by the company.
29. The Evidence Review Group representatives left the meeting.
30. The committee continued to discuss the clinical and cost effectiveness of ibrutinib for treating chronic lymphocytic leukaemia.
 - 30.1. The committee decision was based on consensus.
31. The committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Appraisal of ceritinib for previously treated anaplastic lymphoma kinase-positive non-small-cell lung cancer [ID729]

Part 1 – Open session

32. The Chair welcomed the invited experts: Professor Aileen Clarke and Emma Loveman to the meeting and they introduced themselves to the committee.
33. The Chair welcomed company representatives from Janssen to the meeting.
34. The Chair asked all committee members to declare any relevant interests
 - 34.1. Dr Amanda Adler, Dr Ray Armstrong, Dr Jeff Aronson, Professor John Cairns, Dr Mark Glover, Dr Neil Iosson, Mrs Anne Joshua, Dr Rebecca Kearney, Dr Sanjay Kinra, Dr Miriam McCarthy, Professor Ruairidh Milne, Professor Stephen Palmer, Dr Sanjeev Patel, Professor John Pounsford, Dr Danielle Preedy, Dr Nigel De-Kare Silver, Dr Marta Soares and Dr Nicky Welton all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of ceritinib for previously treated anaplastic lymphoma kinase-positive non-small-cell lung cancer.
35. The Chair asked all NICE Staff to declare any relevant interests.
 - 35.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of ceritinib for previously treated anaplastic lymphoma kinase-positive non-small-cell lung cancer.
36. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
 - 36.1. Professor Aileen Clarke and Emma Loveman declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of ceritinib for previously treated anaplastic lymphoma kinase-positive non-small-cell lung cancer.
37. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
38. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
39. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

40. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

41. Discussion on confidential information continued. This information was supplied by the company.
42. The Evidence Review Group representatives left the meeting.
43. The committee continued to discuss the clinical and cost effectiveness of ceritinib for previously treated anaplastic lymphoma kinase-positive non-small-cell lung cancer.
- 43.1. A vote was taken. The options were:
Option 1: to recommend ceritinib in adults who have previously treated with had crizotinib
Option 2: not to recommend ceritinib
The committee voted for Option 1
Details of the result of this discussion will be included in the confirmed version of these minutes, which will be published during the week commencing 16 May after the publication of all decisions taken at this committee meeting.
44. The committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Date, time and venue of the next meeting

Thursday 5 May 2016 at 10 Spring Gardens, London SW1A 2BU